Connect with us

Business

Third member of prestigious FDA panel resigns over approval of Biogen’s Alzheimer’s drug – CNBC

A third member of a key FDA panel has resigned over the agency’s controversial decision to approve Biogen’s new Alzheimer’s drug,…

Published

on

Article feature image
ADVERTISEMENT

A third member of a key Food and Drug Administration advisory panel has resigned over the agency’s controversial decision to approve Biogen’s new Alzheimer’s drug, Aduhelm, CNBC has learned.
Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Alphabet’s Waymo raises $2.5 bln in fresh funding in a year – Reuters
Article feature image
Tripadvisor launches service that it says offers bigger discounts on hotels, flights – CNBC
Article feature image
General Motors’ electric vehicle plan just got even more expensive – The Verge